Johnson & Johnson Receives FDA Approval for TRUFILL n?BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Johnson & Johnson's INLEXZO delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New long-term data reinforces TREMFYA® as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
FDA approval of CAPLYTA® has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
Johnson & Johnson announces first head-to-head study comparing IMAAVY with an alternative FcRn blocker in generalized myasthenia gravis at AANEM Annual Meeting
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
TREMFYA® , the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
Surface Metals Inc. Engages Barwicki Investor Relations to Lead Strategic Investor Relations and Shareholder Communication Program
Spartan Metals Provides Encouraging Drill Assay Results for Tungstonia Tailings at its Eagle Project, Nevada
Homerun Resources Inc. 100% Owned Subsidiary Homerun Energy SRL Recognized as Key Innovator by European Commission's Innovation Radar
Cartier Reports Significant Gold Resource Growth At Cadillac With 9,953,000 tonnes at a grade of 2.40g/t Au for 767,800 Ounces Measured and Indicated, a 7% Increase and 35,185,000 tonnes at a grade of 2.14g/t Au for 2,416,900 Ounces Inferred, a 48% Increase
